Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| This is also a very healthy segment of our tenant base with substantial revenues and continues to be a critical contributor to innovation and partnerships across our ecosystem |
| Our adjusted EBITDA margin remains very strong at 70% |
| We are quite proud and fortunate to own assets in a scarce asset class |
| This favorable backdrop for this nation's -- one of the nation's most mission-critical industries, which we serve, continues to underpin our business, driving demand for our world-class brand and highly differentiated assets and operations |
| With a deep tenant base relationships across every facet of the industry and in each of our regional ecosystems and of course, the highest quality infrastructure and operations, we get ahead of potential tenant challenges to backfill and further enhance our tenant roster |
| But because of the attractiveness of our product type, Alexandria has been able to make great progress towards reaching our value harvesting goals |
| Alexandria is truly a best-in-class REIT, which pioneered the lab space niche and which I believe has made a metamorphic and innovative and transformational impact on our life science industry for the last 29 years |
| We're very proud of the stellar balance sheet we built since the days of the great financial crisis when we were a small and unrated REIT |
| Given the strong demand for this University Towne Centre asset, we decided to participate in the sale, which captured $32 million in proceeds at a strong 4.5% cap rate, reflective of the high-quality building, tenant credit and the future mark-to-market opportunity we will participate in with our continued ownership |
| It is a testament to the strength, quality and endurance of the Alexandria platform |
| The second quarter was a very strong reporting quarter, generally in line with our 5- and 10-year historical run rates, REIT financial metrics and certainly outside of the rocket ship performance during COVID |
| We had strong FFO per share growth in both the second quarter and the first half approximating 7%, especially in a continuing challenging macro and nicely beating consensus |
| Strong leasing quarter at 1.3 million rentable square feet ahead of the historical run rate of about 1.1 million square feet and NOI was up nicely, almost $200 million for the quarter |
| Positive rental growth, stable occupancy and solid same-store NOI increases also hosted |
| The continuing strength and I think overall solidity of our fortress balance sheet continues |
| Our ability to reiterate and maintain strong guidance, way, all the metrics should demonstrate our continuing confidence and our tenants demand for essential lab space, coupled with our ability to operate successfully in a moderately elevated supply dynamic environment |
| Overall, we are very pleased with the results achieved thus far in our value harvesting asset recycling program |
| What gives us that comfort? I think you've heard us talk about we have a unique brand our mega-campus strategy and our operational excellence, I think, puts us at an advantage to capture opportunities in the marketplace |
| You've seen occupancy in our asset base the way we manage our business have really strong relationships with our tenants and really deliver a level of excellence in operating our buildings |
| Today, I'm going to comment on the solid fundamentals of the secularly growing life science industry, how these fundamentals contribute to the continued vitality and health of Alexandria's best-in-class life science tenant base and innovation as a long-term driver of life science industry growth |
| Illumina is as strong as ever |
| And I think that gives us the confidence that we can achieve our business plan for this year that by the way we articulated last November, and we'll do the same |
| So that is what is giving us the positive outlook |
| Another positive realized this quarter was a notable increase in demand, ranging from 15% to 20% in our top three markets, a sign that perhaps investors are seeing the light at the end of the tunnel when it comes to economic uncertainty, but also likely driven by significant dry powder they need to put to work |
| Despite spreads coming down from the COVID rocket ship numbers, net effective rents remained strong in our operating assets due to their generic build-out, which enables renewals in the re-leasing of vacant space with minimum CapEx |
| That, coupled with some knowing financings that are happening, as companies have been getting good news, to me, it just feels like the wheel starting to turn again momentum is building, and I'm confident it's going to continue |
| And one of the positives that I pointed out in this quarter's comments is that we actually have had, I would call, a significant uptick, 15% to 20% in demand in our top three markets |
| We are pleased to report leasing volume of 1.3 million square feet achieved in the second quarter, which again exceeded our five-year pre-2021 average and is the 13th consecutive quarter where we have achieved a leasing volume above 1 million square feet |
| So the nature of a set of our assets really very, very solid workhorse assets in solid locations with solid tenants and with solid cash flows |
| Private biotechs with tenured management teams, strong differentiated technologies and clear line of sight to value inflection milestones consistent with our own tenant underwriting selection criteria are the ones that continue to rise above the fray |
| Statement |
|---|
| For our current read is that volume will be below 2024 deliveries, likely due to high construction costs, higher cost of capital, a lack of available debt financing and adequate supply currently under construction |
| So Michael, last quarter, in my prepared remarks, I had mentioned that we had seen a weakening in demand |
| The negative sentiment of office buildings outside of cluster locations and a significant amount of capital needed to reposition the asset |
| And I think Peter said or Jenna said, there's always clinical failures in all -- across all modalities and therapeutic classifications |
| It has even hit the somewhat insulated life science industry over the past few quarters, manifested by slower decision-making and the tightening of budgets by executive teams and boards |
| I mean what's happening is -- and I touched on the theme of my comments, I think that uncertainty has really held back the entire economy |
| But I think there's just maybe some confusion or uncertainty over kind of the dollar amount |
| We are lower on G&A than consensus across coverage |
| As you all know, the past few months have had little transactional activity in the broad markets |
| What you've seen is a slower allocation and greater reserves just given the macro market |
| A few days ago, when reading a capital markets report, I came upon the line, uncertainty is arguably the harshest enemy of investing |
| So that doesn't translate to upside there |
| In San Diego, unleased competitive supply remaining to be delivered in 2023 is estimated to be 3.5% of market inventory, which is a decrease of 0.8%, due mainly to projects being delivered with unleased space now reflected in direct vacancy |
| And so net-net, at least through 2024, there's very little upside |
| On the supply front, have you seen a slowdown of some of those non-dedicated life science developers stop-breaking around the new projects? Has that occurred over the past quarter or so? Peter Moglia With a couple of exceptions that are inexplicable, yes |
| They did have an activist attack from icon regarding some management strategies kind of weirdly enough a lot to do about GRAIL, the EU and the FTC took issue with or Illumina acquiring GRAIL |
| Our per share outlook for 2023 was updated to a range plus or minus $0.03 from the midpoint of guidance down from a range plus or minus $0.05 last quarter |
| In 2024, the unleased competitive supply will increase market inventory by 8.8%, a 0.3% reduction due to a downward revision of estimated square footage to be delivered during the year |
| It has held back the life science industry, and that uncertainty is starting to go away and people are starting to realize that there's a lot of dry powder they need to put to work |
| So again, just getting back to where we started with your question, Tony, we'll have to remain very disciplined in our approach, given the macro environment |
Please consider a small donation if you think this website provides you with relevant information